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Background: In Spain, the influenza vaccine effectiveness (VE) was estimated in the last three seasons using the
observational study cycEVA conducted in the frame of the existing Spanish Influenza Sentinel Surveillance System.
The objective of the study was to estimate influenza vaccine effectiveness (VE) against medically attended,
laboratory-confirmed influenza-like illness (ILI) among the target groups for vaccination in Spain in the 2011–2012
season. We also studied influenza VE in the early (weeks 52/2011-7/2012) and late (weeks 8-14/2012) phases of the
epidemic and according to time since vaccination.
Methods: Medically attended patients with ILI were systematically swabbed to collect information on exposure,
laboratory outcome and confounding factors. Patients belonging to target groups for vaccination and who were
swabbed <8 days after symptom onset were included. Cases tested positive for influenza and controls tested
negative for any influenza virus. To examine the effect of a late season, analyses were performed according to the
phase of the season and according to the time between vaccination and symptoms onset.
Results: The overall adjusted influenza VE against A(H3N2) was 45% (95% CI, 0–69). The estimated influenza VE
was 52% (95% CI, -3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135 to 74) at 3.5 months, 3.5-4 months,
and >4 months, respectively, since vaccination. A decrease in VE with time since vaccination was only observed in
individuals aged ≥ 65 years. Regarding the phase of the season, decreasing point estimates were only observed in
the early phase, whereas very low or null estimates were obtained in the late phase for the shortest time interval.
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Conclusions: The 2011–2012 influenza vaccine showed a low-to-moderate protective effect against medically
attended, laboratory-confirmed influenza in the target groups for vaccination, in a late season and with a limited
match between the vaccine and circulating strains. The suggested decrease in influenza VE with time since
vaccination was mostly observed in the elderly population. The decreasing protective effect of the vaccine in the
late part of the season could be related to waning vaccine protection because no viral changes were identified
throughout the season.
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immunityBackground
The viral antigens included in seasonal influenza vaccines
are revised annually in anticipation of expected changes in
circulating influenza viruses. Vaccine effectiveness (VE)
cannot be presumed from historical data [1].
Evidence from trials and observational studies suggests
that presently available influenza vaccines can provide
only moderate overall protection against infection and
illness [2]. However, influenza vaccination remains the
most cost-effective public health prevention measure
currently available for reducing the morbidity and mor-
tality associated with influenza infection, as vaccination
is strongly recommended every year by the international
health authorities [3].
Influenza vaccination in Spain is annually offered free
of charge to individuals at high-risk of influenza compli-
cations and to those over 59/ 64 years of age (depending
on the region) [4].
Since the 2008–2009 season, Spain has been partici-
pating in the European Centre for Disease Prevention
and Control(ECDC)-funded project I-MOVE [“Monitor-
ing the influenza vaccine effectiveness in the European
Union and European Economic Area (EU/EEA)”] with
the cycEVA study within the framework of the Spanish
Influenza Sentinel Surveillance System (SISSS) [5-9]. For
at second year, in February 2012, the I-MOVE mul-
ticentre case–control study and cycEVA study were able
to provide an intra-seasonal influenza VE estimate
[10,11]. The results suggested a low-to-moderate pro-
tective effect of the seasonal 2011–2012 vaccine in
preventing medically attended, laboratory-confirmed
influenza in the target groups for vaccination. Final
estimates suggested lower values later in the season
[12-14]. The duration of the protection provided by
influenza vaccines is debated and could be related to
several factors, including age and the type/subtype of
influenza infection [15].
We aimed to present the overall and age-specific end-
of-season effects of the 2011–2012 influenza vaccine on
preventing medically attended, laboratory-confirmed
influenza-like illness (ILI) in the groups targeted for vac-
cination. Because the influenza season peaked unusuallylate in Spain, we also studied influenza VE in the early
and late phases of the season and according to time
since vaccination.
Methods
Study design and data collection
Seven regional influenza surveillance networks within
primary care in different parts of Spain participated in
the cycEVA study (test-negative design). The participa-
ting sentinel general practitioners and paediatricians
(GPs) (231) adhered to a common protocol specifically
designed for the European multicentre case–control
study [16]. The physicians selected patients according to
a definition based on the EU ILI case definition [7,12]
and systematically swabbed the first two patients per
week aged <65 years and all patients ≥65 years who
presented to the GP’s office with ILI. Practitioners also
collected the following information for each recruited
patient: demographic and clinical data, vaccination sta-
tus for 2011–2012 trivalent seasonal influenza vaccine
(date of vaccination and type of vaccine received),
laboratory data and data on potentially important con-
founders (previous influenza vaccination, the presence of
any chronic condition, smoking history, any hospitalisa-
tion for chronic conditions in the previous 12 months,
and the number of outpatient visits for any reason in the
previous 12 months [7]. Missing information was not
observed for the 2011–2012 vaccination status, and only
two records were missing the previous vaccination
status. The prevalence of missing data ranged from 0.7%
to 1.8% for other variables related to possible confoun-
ding factors.
This study started in week 52/2011 (December 25,
2011), during which the ILI rate exceeded the winter base-
line level and finished on week 18/2012 (May 6, 2012),
which proceeded two consecutive weeks without any ILI
cases testing positive for influenza.
Identification of cases and controls
Cases were ILI patients who tested positive for influenza
virus using reverse transcription polymerase chain reac-
tion (RT-PCR) and/or cell culture. Controls were ILI
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virus. We considered a patient vaccinated if the patient
had received the 2011–2012 influenza vaccine at least
14 days before ILI symptom onset.
VE analysis
We restricted the analysis to patients who belonged to
the target groups for vaccination and who were swabbed
less than eight days after the onset of symptoms. We
undertook two analyses of VE: for influenza (all strains)
and for A(H3N2) influenza virus restricted to the weeks
in which this strain predominated.
To check the effect of the late season on the effective-
ness of the vaccine, we estimated influenza VE according
to the 2011–2012 influenza season phase, splitting the
season into two periods: an early phase before the epi-
demic peak (weeks 52/2011-7/2012) and a late phase
after the peak (weeks 8-14/2012). To characterise a pos-
sible waning vaccine protection after vaccination, we
also calculated influenza VE according to time since
vaccination (the number of days between the date of
vaccination and onset of symptoms) using three equal
time intervals according to the distribution of the time
since vaccination variable to facilitate comparisons
between sub-groups. For trend evaluation we treated
time since vaccination as a continuous variable in a
logistic model to test the null hypothesis of beta = 0. We
compared the characteristics of cases and controls using
a t-test, Fisher’s exact test, a chi-squared test or the
Mann–Whitney test, as appropriate. The age effect was
taken into account by adjustment and by performing a
stratified analysis of individuals <65 years and ≥65 years.
We estimated influenza VE as 1 minus the odds ratio
(OR). To estimate the adjusted influenza VE, we used a
logistic regression model that includes potential con-
founders that changed the crude OR by more than 10%
and were related to both the exposure and the outcome
[17]. We also adjusted for calendar time by using the
week of swabbing as a categorical variable. Effect modifi-
cation by age was assessed by likelihood ratio tests. We
conducted all statistical analyses using Stata version 11.
Laboratory methods
A subset of influenza isolates was sent to the National
Influenza Centre (WHO Influenza Centre) for influenza-
specific gene sequencing and genetic characterisation.
The isolates were genetically characterised by sequen-
cing the HA1 fragment of the viral haemagglutinin gene.
Phylogenetic analysis was performed to characterise the
specific strains of influenza A and B viruses.
We analysed the temporal trend of genetically
characterised influenza A(H3N2) viruses in Spain in the
entire SISSS using a simple linear regression model in
which the logarithms of the relative weekly frequenciesof the influenza A(H3N2) viruses, which were distinct
from the vaccine virus, were considered as the
dependent variable, and time (weeks) was the independ-
ent variable.
This observational study was part of Spanish influenza
surveillance activities. Only anonymous personal infor-
mation was collected and patients gave verbal informed
consent to participate in the study. Consequently, no
ethical approval by the Human Research Ethics Commit-
tee therefore was required.
Results
Description of 2011–2012 influenza season in Spain
In Spain, influenza activity in 2011–2012 reached its
peak in mid-February (week 7/2012), with 251 ILI cases/
100,000 people. The influenza season was largely domi-
nated by influenza A(H3N2) with an increasing contri-
bution of influenza B virus, which became dominant
after the epidemic period. In the seven cycEVA regions
we observed a similar viral circulation pattern and evo-
lution of influenza activity (Figure 1).
Patient characteristics
In total, 231 practitioners agreed to participate in the
study and 197 (85%) recruited at least one ILI patient.
From the target groups for vaccination, 382 (27% of all
patients) were recruited. All patients had information on
their laboratory results and vaccination status, and only
four individuals were swabbed more than seven days
after symptom onset (Figure 2). After applying the exclu-
sion criteria, we included 99% (378) of the recruited pa-
tients belonging to the target groups for vaccination in
the analysis: 253 laboratory-confirmed influenza cases
[226 A(H3N2), 1 A(H1N1)pdm09, and 26 B] and 125
test-negative controls.
The demographic and clinical characteristics of the 226
laboratory-confirmed influenza A(H3N2) cases and the
116 test-negative controls belonging to the population
targeted for vaccination and included into the analysis, are
displayed in Table 1. Controls were significantly younger
than cases, with median ages of 53 and 63 years, respect-
ively (P = 0.011). Compared with cases, controls were
more likely to have certain chronic conditions (62.9% vs
51.8%; P = 0.049) and included a higher proportion of
smokers (19.1% vs 11.2%; P = 0.046). Although the median
time since vaccination was longer in cases than in controls
(116 and 109 days, respectively), this difference was not
statistically significant.
VE results
The overall crude influenza VE among the target groups
for vaccination against any type or A(H3N2) influenza
virus was estimated at 8% (95% CI, -43 to 41) and 3%
(95% CI, -53 to 39), respectively. The adjusted influenza
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Figure 1 Controls and confirmed cases by type/subtype of influenza virus, and weekly incidence, cycEVA 2011-12 study, Spain.
382 ILI patients recruited belonging to 
the target groups for vaccination
4 ILI patients excluded for 
onset-swabbing > 7 days
378 ILI patients: 253 cases and 125 controls
26 ILI patients excluded as 
confirmed with B influenza virus
1 ILI patients excluded as confirmed with A(H1N1)pdm09 influenza virus
A(H3N2) influenza
infection 
351 ILI patients: 226 cases and 125 controls
Any type of influenza 
infection 
Figure 2 Flowchart of data exclusion and analysis outcomes, target groups for vaccination, cycEVA 2011-12 study, Spain.
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Table 1 Characteristics of influenza A(H3N2) confirmed cases (N = 226) and test-negative controls (N = 116) in target
group for vaccination, cycEVA 2011–12 study (weeks 52/2011 – 14/2012), Spain
Variables Controls no./total no. (%)a A(H3N2) cases no./
total no. (%)a
P valueb
Median age (range years) 53 (3–87) 63 (3–93) 0.011
Age group (years)
0–4 4/116 (3.2) 5/226 (2.2) 0.088
5–14 8/116 (6.5) 14/226 (6.2)
15–64 69/116 (58.5) 107/226 (47.3)
≥65 35/116 (31.8) 100/226 (44.2)
Sex: male 52/116 (46.9) 106/226 (46.9) 0.716
Any chronic condition reported 73/116 (62.9) 117/226 (51.8) 0.049
Pregnancy 3/116 (2.6) 6/226 (2.6) 0.970
Obesityc 6/116 (4.9) 12/226 (5.3) 0.957
Any hospitalization 4/116 (3.4) 11/226 (4.9) 0.544
Median GP visits (range number) 5 (0–32) 5 (0–32) 0.782
Smoker 23/115 (19.1) 25/223 (11.2) 0.046
Swabbing less 4 days 108/116 (93.1) 217/226 (96.0) 0.240
Median time since vaccination (range days) 109 (39–151) 116 (62–166) 0.432
Vaccine coverage
By seasonal vaccine
Seasonal 2011-12 46/116 (39.7) 88/226 (38.9) 0.898
Seasonal 2010-11 40/116 (34.5) 75/224 (33.5) 0.853
By age groups
0–4 years 1/4 (25.0) 2/5 (40.0) 0.635
5–14 years 1/8 (12.5) 2/14 (14.3) 0.907
15–64 years 19/69 (27.6) 19/107 (17.8) 0.124
≥65 years 25/35 (71.4) 65/100 (65.0) 0.487
GP: general practitioners and paediatricians.
aCases and controls recruited between weeks 52/2011 – 14/2012 and with an interval between symptom onset and swabbing of less than eight days.
bNon parametric test of the median or Chi-square test or Fisher’s exact test, when appropriate.
cDefined as body mass index ≥ 40 kg/m2.
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week of swabbing were 47% (95% CI, 7–70) against any
type of influenza virus and 45% (95% CI, 0–69) against
A(H3N2) influenza virus (data not shown).
Adjusted influenza VE estimates against A(H3N2)
according to time since vaccination were 52% (95% CI, -
3 to 78), 40% (95% CI, -40 to 74) and 22% (95% CI, -135
to 74) for 3.5 months, 3.5-4 months, and >4 months
since vaccination, respectively (data not shown) (p for
trend = 0.109).
The analysis of influenza VE according to time since
vaccination and age group is shown in Table 2. Among
individuals ≥65 years the adjusted VE against A(H3N2)
decreased from 85% (95% CI, 18–97), for patients vacci-
nated three months before the onset of symptoms to a
null estimate for individuals vaccinated more than four
months before the onset symptoms (p for trend = 0.211).
Decreasing VE with time since vaccination was notobserved in patients <65 years (p for trend = 0.335)
(Table 2). Regarding effect modification, there was no
evidence that VE varied by age (p = 0.80).
In the early influenza phase the adjusted influenza VE
against A(H3N2) was 52% (95% CI, 4–76), compared
with 28% (95% CI, -124 to 77) in the late phase (data
not shown).
Analysis according to time since vaccination in the
different influenza phases showed that in the early influ-
enza phase, adjusted VE estimates against A(H3N2) de-
creased with time since vaccination from 95% (95% CI,
45–99) at three months since vaccination to 36% (95%
CI, -71 to 76) at more than 3.5 months since vaccination
(Table 3). This decreasing trend with time since vacci-
nation was not statistically significant (p for trend =
0.119). In the late influenza phase, adjusted influenza VE
estimates were very low or null in the three studied
strata (Table 3).
Table 2 Effectiveness of the trivalent influenza 2011–12 vaccine against influenza A(H3N2) in target group for
vaccination by age group, according to the time since vaccination, cycEVA study (weeks 52/2011 – 14/2012), Spain
Study population Time since vaccination Cases and
controls (N/N)
Vaccinated cases
and controls (N/N)
OR Influenza VE %
(95% CI)
Trend p valuec
≥65 years 49–88 days 39/17 4/7 Crude 84 (33;96) 0.211
Adjusted 85 (18;97)a
89–127 days 72/24 37/14 Crude 24 (−92;70)
Adjusted 33 (−102;78)a
128–166 days 58/14 23/4 Crude −64 (−487;54)
Adjusted −376 (−4332;49)a
<65 years 39–75 days 104/64 1/4 Crude 85 (−33;98) 0.335
Adjusted 84 (−138;99)b
76–111 days 114/66 11/6 Crude −7 (−203;62)
Adjusted 19 (−149;73)b
112–148 days 113/71 10/11 Crude 47 (−32;79)
Adjusted 58 (−19;86)b
aModel adjusted for age groups (65–75, 76–85, 86–95 and 95–105 years), and week of swabbing. bModel adjusted for age groups (0–4, 5–14, 15–44 and 45–
64 years), and week of swabbing. cTest for trend using time since vaccination as continuous.
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Sequence analysis of the product of amplification
targeting the full-length HA1 segment of hemagglutinin
showed that most of the studied influenza A virus strains
clustered into three genetic groups defined by specific
amino acid mutations compared with A/Perth/16/2009
(Figure 3). Among the 127 A(H3N2) sequenced strains,
40% clustered into the group A/England/259/2011, 36%
clustered into the group A/Victoria/361/2011 and 22%
clustered into the group A/Iowa/19/2010. The remaining
two A(H3N2) viruses (1%) clustered into the group A/
Stockholm/18/2011.Table 3 Effectiveness of the trivalent influenza 2011–12 vaccin
by time since vaccination, in the early and late phase of the se
Influenza
activity phasea
Time since vaccination Cases and
controls (N/N)
Vac
and
Early phase 45–75 days 110/63
76–105 days 128/66
106–135 days 131/64
Late phase 39–81 days 29/16
82–123 days 47/21
124–166 days 55/26
aEarly phase: December 2011 – first half of February 2012; Late phase: Second half
and >64 years), and week of swabbing. cModel adjusted for age groups (0–4, 5–14,
using time since vaccination as continuous.The weekly proportion of influenza A(H3N2) viru-
ses distinguishable from the vaccine virus in Spain
was similar during the entire study period, ranging
from 91%-100%, with a not significant weekly per-
centage change of −0.21% (95% CI, -0.64 to 0.22).
The only characterised A(H1N1)pdm09 virus clustered
into A/StPetersburg/100/2011. Regarding influenza B,
the Yamagata lineage (n = 16, 94%) viruses predominated
over those of the Victoria lineage (n = 1, 6%). Most of
the Yamagata lineage viruses clustered into the B/
Bangladesh/3333/2007 genetic clade, and only one clus-
tered into the B/Brisbane/3/2007 group.e against influenza A(H3N2) in target group for vaccination
ason, cycEVA study (weeks 52/2011 – 14/2012), Spain
cinated cases
controls (N/N)
OR Influenza VE %
(95% CI)
Trend p valued
1/8 Crude 94 (48;99) 0.119
Adjusted 95 (45;99)b
19/11 Crude 13 (−96;53)
Adjusted 48 (−31;80)c
22/9 Crude −23 (−186;47)
Adjusted 36 (−71;76)c
0/1 Crude 0 0.518
Adjusted 0
18/6 Crude −55 (−372;49)
Adjusted −9 (−379;75)b
26/11 Crude −22 (−213;52)
Adjusted 15 (−214;77)b
of February – April 2012. bModel adjusted for age groups (0–4, 5–14, 15–64
15–64 and >64 years), smoking habit, and week of swabbing. dTest for trend
Figure 3 Phylogenetic tree of the influenza A(H3N2) viruses HA1 fragment of the hemagglutinin gene, cycEVA 2011-12 study, Spain.
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virus strains among age groups patients or between
vaccinated and non vaccinated patients.
Discussion
The results for the 2011–2012 season of the cycEVA
study show a low-to-moderate protective effect for the
2011–2012 seasonal trivalent influenza vaccine against
medically attended, laboratory-confirmed influenza in
the target groups for vaccination, consistent with Spanish
and European estimates [11-14]. In a late influenza season
with a limited match between vaccine and circulating
strains, we may suggest waning protection of the influenza
vaccine 2011–2012 in the elderly with time since vaccin-
ation, although the trends were not statistically significant
[12-14].
Although this study runs within the framework of the
current SISSS, it is an observational study that followed
a common protocol to be part of the European
multicentre case–control study I-MOVE. Using the EU
ILI case definition, GPs performed systematic sampling
and collected high quality information on the main
confounding factors described in the literature, thus
reducing possible confounding bias.By restricting the study to the epidemic period we also
reduced the possible bias resulting from the inclusion of
ILI patients when influenza viruses are not circulating
[18]. During this period of intense influenza activity,
influenza positivity was higher than 50%, such that a
higher number of cases than controls was included in
the analysis.
The test-negative study design is becoming an increas-
ingly well-established approach to measuring influenza
VE and generates the highest estimates of VE [18-22].
This design avoids confounding by the propensity to
seek care within the control group, which is negative for
influenza, thus providing better comparability with the
confirmed cases [23-27]. In addition, study participants
were selected by practitioners according to a systematic
sampling procedure before either the patient or the phy-
sicians knew the case and control status of the patients.
This protocol should minimise selection bias [23]. By
restricting our analysis to ILI patients swabbed less than
eight days after the onset of symptoms, we tried to
minimise the possibility of misclassification because of
false-negative RT-PCR results that could contribute to
an underestimation of influenza VE. In addition, adjus-
ting for swabbing week helped to overcome another
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ling the analysed data for calendar time [18]. Neverthe-
less, as with any observational design, we cannot rule
out residual bias and confounders [23,28].
The 2011–2012 influenza season was characterised by
several noteworthy aspects in Spain. First, this season was
notably late, as in most of the northern hemisphere’s tem-
perate zone with the exception of North Africa [29]. The
epidemic peak was not reached in Spain until mid-
February 2012, whereas peaks are usually in late December
or early January [30]. Second, there was a predominant
circulation of A(H3N2) influenza virus with a minimal
contribution of the A(H1N1)pdm09 influenza subtype,
which has been the predominant subtype since the 2009
pandemic. Third, there was a limited match between the
vaccine and circulating A(H3N2) strains [29,31].
Our global adjusted influenza VE estimate against A
(H3N2) influenza infection, 45% (95% CI, 0–69), was
consistent with the VE estimated in Australia for the
2011 season against influenza A(H3) (58%, 95% CI, -53
to 89) [32] and with the results of previous studies in
years with a predominant circulation of seasonal influ-
enza A(H3N2) virus, which determined influenza VE to
range from 10% to 68%, depending on the degree of
antigenic match [20,21,24,33]. Although the effectiveness
of the influenza vaccine is often less pronounced during
seasons with antigenic mismatch between the vaccine
and the circulating strains [34], in certain influenza
season’s, antigenic changes occur without resulting in
any apparent loss of influenza VE [35].
Several factors might have contributed to the low to
moderate protective effect of the 2011–2012 trivalent
influenza vaccine. Firsly, the circulating A(H3N2) influ-
enza viruses in Spain clustered into several genetic
groups that were reported to be antigenically and genet-
ically distinct from the vaccine virus A/Perth/16/2009
[31]. This limited match was observed globally in the
northern hemisphere [31], resulting in a change in the
WHO recommended A(H3) vaccine strain for 2012–
2013 in the northern hemisphere [36].
Second, in an unusually late influenza season [29,30],
with a time lag between the vaccination campaigns and
the start of the epidemic that was longer than in previ-
ous seasons, our results suggested a decrease in the pro-
tective effect of the 2011–2012 trivalent influenza
vaccine with time since vaccination. This pattern was
also observed in other studies [12-14].
A decreasing influenza VE over time could be related
to increasing changes in circulating viruses towards the
end of the season and/or potentially waning immunity
in the months following vaccination [12,29]. Phylogen-
etic analyses of the circulating influenza viruses in Spain
did not support the hypothesis of an increased emer-
gence of antigenically drifted A(H3) variants during theinfluenza season in Spain. There was a presence of
mismatched influenza viruses since the beginning of the
2011–2012 Spanish influenza season, with a similar
weekly proportion of circulating changed A(H3N2)
influenza strains throughout the entire study period.
Re-analysing influenza VE data for the preceding
season 2010–2011 [7] we also observed decreasing
influenza VE against A(H1N1)pdm09 in target groups
for vaccination, from 62% (95% CI, -1 to 85) to 44%
(95% CI, -122 to 86) for those vaccinated within three
months or more than three months before the onset of
symptoms, respectively. This lower decrease in VE over
time (26%) observed in the previous season relative to
the VE in our study for the 2011–2012 season (46%, data
not shown) highlights the possibility that even in a
usually timed season with a predominant circulation of a
well-matched A(H1N1)pdm09 influenza virus, the influ-
enza vaccine exhibits a degree of waning immunity.
To further explore the decrease in the protective effect
of the vaccine with time since vaccination, we deter-
mined influenza VE by the phase of the season. We
observed a decreasing influenza VE with time since
vaccination during the early phase, from a high influenza
VE of 95% (95% CI :45–99) at three months since vacci-
nation, to a lower influenza VE point estimate of 36%
(95% CI: -71 to 76) at more than 3.5 months since
vaccination.
In the late phase, influenza VE estimates were compat-
ible with null vaccine protection since shortly after vac-
cination. This finding is consistent with the finding that
patients included in the late-phase subgroup had a me-
dian time since vaccination that was nearly one month
longer that that in individuals in the early phase
(128 days, range: 39–166 days vs 103 days, range: 45–
135 days, respectively).
Together, these findings could reinforce the hypothesis
of the possibly waning protection of the influenza
vaccine. However, these results must be interpreted with
caution because the study was limited by its small sam-
ple size. Therefore, although point estimates showed a
substantial decrease with time since vaccination in the
early phase, we could not demonstrate a significant
decreasing influenza VE trend over time.
By age group, a decline in influenza VE with time since
vaccination was also observed only in patients ≥65 years,
although interpretation is limited by small sample size,
which likely precluded the observation of a significant
trend with time since vaccination [37].
A significant reduction in antibody titres 5–6 months
after vaccination and, therefore, waning immunity
following seasonal vaccination has been demonstrated in
the elderly [38,39].
However, in our study, we also obtained a higher influ-
enza VE point estimate shortly after vaccination among
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(95% CI: 6–91) and 45% (95% CI: -114 to 87), respect-
ively [40]. Conflicting results have been reported
concerning the association between older age and the
response to influenza vaccines. Several authors have
found a reduced response in aged subjects, but others
have reported no difference or even better results
compared with younger control subjects [15,41]. Other
studies showed that subjects vaccinated in every epi-
demic season for several years were protected against
influenza despite low titres of anti-haemagglutinin
antibodies [42]. Recently, studies performed during
2010–2011 influenza season demonstrated a higher
influenza VE in patients vaccinated with both the
current 2010–2011 and the previous 2009–2010 influ-
enza vaccines in all age groups [7,43] and in a popula-
tion with major chronic conditions [44]. In our study, a
higher proportion of the elderly population (59%) com-
pared with individuals <65 years (15%) was vaccinated
with both the 2011–2012 vaccine and previous 2010–
2011 seasonal influenza vaccines (p = 0.000). This factor
could explain the higher influenza VE estimate obtained
in the elderly relative to the younger group.
It is worth noting that currently there are few studies
analysing influenza VE according to the time when the
vaccination was given [12-14]. In addition, although
levels of antibodies to seasonal inactivated influenza vac-
cine decline in the months following vaccination, this
phenomenon does not necessarily reflect clinical VE [15].
Consequently, although limited by their statistical power,
our results contribute to the currently available scientific
evidence on influenza VE, which have been poorly studied
so far. Nevertheless, how antigenic drift in circulating
influenza strains could affect influenza VE in a late season
remains unclear. Further studies are needed to elucidate
the impact of these and other possible factors on the pro-
tective effect of the influenza vaccine.
Our results were also limited by low vaccine coverage
(VC), especially in individuals <65 years. In addition, we
cannot extrapolate influenza VE estimates for older
people to all elderly populations [5] because influenza
VE in the ≥65-years-old test-negative controls was
higher than VC in the same age group belonging to the
GPs’ catchment area (70% vs. 56%). Another limitation
of our study arises from the recommendation of swab-
bing to all ILI patients ≥65 years, a subgroup of the
population targeted for vaccination that was included in
our study, what could have introduced a selection bias
that affected the influenza VE estimates. However, we
believe that the target group for vaccination is a homo-
geneous study population with regard to vaccination, the
main exposure of interest, because the study participants
had more equal access to vaccination than the total
population.Because annual influenza vaccination is recommended
by public health authorities, it is crucial to annually
evaluate influenza immunisation programs and issue
recommendations. This study has fulfilled this mission
over the past four years by developing and implementing
a sustainable system for annually assessing of influenza
VE vaccination in Spain and Europe, as part of the I-
MOVE project. Over two consecutive years, preliminary
and end-of-season influenza VE estimates supported the
feasibility of generating and disseminating preliminary
influenza VE estimates while virus circulation is ongoing
[11,45].
The low-to-moderate protective effect of the 2011–
2012 influenza vaccine in Spain that was observed in this
study is in line with evidence from trials and observa-
tional studies to date [2]. This finding highlights subopti-
mal vaccine performance in most years within the
presently available influenza vaccines, with performance
seldom exceeding 60%, thereby underscoring the urgent
need for better and longer-lasting protective vaccines
[22,46]. Moreover, results on influenza VE, together with
virological studies, should contribute to decision-making
for the annual selection of influenza vaccine strains.
After five editions, the test-negative design of the
cycEVA study has provided reliable information on annual
influenza VE in Spain and may have important implica-
tions for the design of control influenza strategies.
Conclusions
In conclusion, the 2011–2012 trivalent influenza vaccine
in Spain showed a low-to-moderate protective effect in
the groups for whom vaccination was recommended.
Influenza VE estimates in the early phase of the sea-
son, for patients vaccinated within three months of the
onset of symptoms reinforce the importance of official
recommendations for annual influenza vaccination.
Decreasing influenza VE over time in the elderly popula-
tion has been suggested, but it is not possible to disen-
tangle the respective roles of the waning protection of
the influenza vaccine, changes in the circulating viruses
during the season and other unknown factors.
Our findings have important implications that can
guide national policy makers in the design of influenza
control strategies when facing future late influenza sea-
sons. Moreover, the data support an urgent need for the
development of new influenza vaccines providing better
and longer-lasting protection.
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